Dossier assessment
Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V
-
Dossier assessment
Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V
Dossier assessment
Adult patients with symptomatic anaemia associated with chronic kidney disease (CKD) who are on chronic maintenance dialysis
Added benefit not proven
Press releases
Vadadustat for symptomatic anaemia associated with chronic kidney disease: missed opportunity
Additional information
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.
Project details
- Project no.
- A24-67
- Commission
- Commission awarded on 30.05.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-67_en
Connected Projects
-
Addendum
Vadadustat (symptomatic anaemia associated with dialysis-dependent chronic kidney disease) – Addendum to Project A24-67
Status: Commission completed